Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.

Cancer risk assessments for inorganic arsenic have been based on human epidemiological data, assuming a linear dose response below the range of observation of tumors. Part of the reason for the continued use of the linear approach in arsenic risk assessments is the lack of an adequate biologically based dose response (BBDR) model that could provide a quantitative basis for an alternative nonlinear approach. This paper describes elements of an ongoing collaborative research effort between the CIIT Centers for Health Research, the U.S. Environmental Protection Agency, ENVIRON International, and EPRI to develop BBDR modeling approaches that could be used to inform a nonlinear cancer dose response assessment for inorganic arsenic. These efforts are focused on: (1) the refinement of physiologically based pharmacokinetic (PBPK) models of the kinetics of inorganic arsenic and its metabolites in the mouse and human; (2) the investigation of mathematical solutions for multi-stage cancer models involving multiple pathways of cell transformation; (3) the review and evaluation of the literature on the dose response for the genomic effects of arsenic; and (4) the collection of data on the dose response for genomic changes in the urinary bladder (a human target tissue for arsenic carcinogenesis) associated with in vivo drinking water exposures in the mouse as well as in vitro exposures of both mouse and human cells. An approach is proposed for conducting a biologically based margin of exposure risk assessment for inorganic arsenic using the in vitro dose response for the expression of genes associated with the obligatory precursor events for arsenic tumorigenesis.

[1]  Charles Auffray,et al.  Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. D. Del Razo,et al.  Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in mice following acute oral administration of arsenate. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  Emanuel Parzen,et al.  Stochastic Processes , 1962 .

[4]  D. Yu.  A pharmacokinetic modeling of inorganic arsenic: a short-term oral exposure model for humans. , 1999, Chemosphere.

[5]  K. Jan,et al.  Arsenite retards DNA break rejoining by inhibiting DNA ligation. , 1997, Mutagenesis.

[6]  C. Klein,et al.  Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk? , 2005, Toxicology and applied pharmacology.

[7]  Kathleen Shordt,et al.  Arsenic in drinking water. , 2001, Journal of environmental health.

[8]  M. Andersen,et al.  Probing the control elements of the CYP1A1 switching module in H4IIE hepatoma cells. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[9]  L. Marnett,et al.  Alterations in gene expression induced by the lipid peroxidation product, 4-hydroxy-2-nonenal. , 2005, Chemical research in toxicology.

[10]  M. Little,et al.  Are two mutations sufficient to cause cancer? Some generalizations of the two-mutation model of carcinogenesis of Moolgavkar, Venzon, and Knudson, and of the multistage model of Armitage and Doll. , 1995, Biometrics.

[11]  Melvin E Andersen,et al.  New directions in incidence-dose modeling. , 2005, Trends in biotechnology.

[12]  K. Kitchin,et al.  Arsenite binding to synthetic peptides based on the Zn finger region and the estrogen binding region of the human estrogen receptor-alpha. , 2005, Toxicology and applied pharmacology.

[13]  J. Yager,et al.  Physiologically Based Pharmacokinetic Modeling of Arsenic in the Mouse , 2004, Journal of toxicology and environmental health. Part A.

[14]  R. Calderon,et al.  Arsenic : exposure and health effects , 1997 .

[15]  P O Droz,et al.  A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. , 1996, Toxicology and applied pharmacology.

[16]  J. Wiencke,et al.  Enhancement of chromosomal damage by arsenic: implications for mechanism. , 1993, Environmental health perspectives.

[17]  T. E. Harris,et al.  The Theory of Branching Processes. , 1963 .

[18]  M. Vahter.  Mechanisms of arsenic biotransformation. , 2002, Toxicology.

[19]  K. Salnikow,et al.  Backing into cancer: effects of arsenic on cell differentiation. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[20]  J. Berenson,et al.  Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. , 2006, Clinical lymphoma & myeloma.

[21]  X. Jin,et al.  Effect of arsenic on transcription factor AP-1 and NF-kappaB DNA binding activity and related gene expression. , 2002, Toxicology letters.

[22]  D Hattis,et al.  Human variability in susceptibility to toxic chemicals--a preliminary analysis of pharmacokinetic data from normal volunteers. , 1987, Risk analysis : an official publication of the Society for Risk Analysis.

[23]  M. Ihnat,et al.  Arsenic stimulates angiogenesis and tumorigenesis in vivo. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[24]  J. Wiencke,et al.  Inhibition of poly(ADP-ribose) polymerase by arsenite. , 1997, Mutation research.

[25]  Andre E. Nel,et al.  How Exposure to Environmental Tobacco Smoke, Outdoor Air Pollutants, and Increased Pollen Burdens Influences the Incidence of Asthma , 2006, Environmental health perspectives.

[26]  M. Andersen,et al.  Mode of Action Studies for Assessing Carcinogenic Risks Posed by Inorganic Arsenic , 1999 .

[27]  K. Crump,et al.  A Numerical Solution to the Nonhomogeneous Two‐Stage MVK Model of Cancer , 2005, Risk analysis : an official publication of the Society for Risk Analysis.

[28]  M. Andersen,et al.  Requirements for a Biologically Realistic Cancer Risk Assessment for Inorganic Arsenic , 1999 .

[29]  R Julian Preston,et al.  Quantitation of molecular endpoints for the dose-response component of cancer risk assessment. , 2002, Toxicologic pathology.

[30]  A. J. Gandolfi,et al.  Arsenite and monomethylarsonous acid generate oxidative stress response in human bladder cell culture. , 2006, Toxicology and applied pharmacology.

[31]  V. Devesa,et al.  Tissue dosimetry, metabolism and excretion of pentavalent and trivalent dimethylated arsenic in mice after oral administration. , 2005, Toxicology and applied pharmacology.

[32]  D. Yu,et al.  A physiologically based pharmacokinetic model of inorganic arsenic. , 1999, Regulatory toxicology and pharmacology : RTP.

[33]  Liang Jh,et al.  Inhibition of DNA ligase activity by arsenite: a possible mechanism of its comutagenesis. , 1989 .

[34]  S. Waters,et al.  Elucidating the pathway for arsenic methylation. , 2004, Toxicology and applied pharmacology.

[35]  H. Clewell,et al.  Quantitative Estimates of Risk for Noncancer Endpoints , 2005, Risk analysis : an official publication of the Society for Risk Analysis.

[36]  J. Wiencke,et al.  Specificity of arsenite in potentiating cytogenetic damage induced by the DNA crosslinking agent diepoxybutane , 1992, Environmental and molecular mutagenesis.

[37]  Julia S Kimbell,et al.  Human respiratory tract cancer risks of inhaled formaldehyde: dose-response predictions derived from biologically-motivated computational modeling of a combined rodent and human dataset. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[38]  J. Ward,et al.  Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. , 2003, Toxicology and applied pharmacology.

[39]  Janice W Yager,et al.  Kinetics of arsenic methylation by freshly isolated B6C3F1 mouse hepatocytes. , 2006, Chemico-biological interactions.

[40]  M. E. Meek,et al.  Is Ingested Inorganic Arsenic a “Threshold” Carcinogen? , 1996 .

[41]  Julia S Kimbell,et al.  Biologically motivated computational modeling of formaldehyde carcinogenicity in the F344 rat. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.